Rocket Pharmaceuticals, Inc. (RCKT)
2.565
-0.06
(-2.47%)
USD |
NASDAQ |
Oct 09, 16:00
2.59
+0.02
(+0.97%)
After-Hours: 20:00
Rocket Pharmaceuticals Net Income (Quarterly) : 123.21M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 123.21M |
| March 31, 2026 | -47.59M |
| December 31, 2025 | -42.54M |
| September 30, 2025 | -50.33M |
| June 30, 2025 | -68.92M |
| March 31, 2025 | -61.33M |
| December 31, 2024 | -60.33M |
| September 30, 2024 | -66.72M |
| June 30, 2024 | -69.65M |
| March 31, 2024 | -62.05M |
| December 31, 2023 | -59.66M |
| September 30, 2023 | -61.90M |
| June 30, 2023 | -65.70M |
| March 31, 2023 | -58.34M |
| December 31, 2022 | -66.72M |
| September 30, 2022 | -57.76M |
| June 30, 2022 | -54.40M |
| March 31, 2022 | -42.98M |
| December 31, 2021 | -44.25M |
| September 30, 2021 | -50.12M |
| June 30, 2021 | -34.52M |
| March 31, 2021 | -40.18M |
| December 31, 2020 | -60.92M |
| September 30, 2020 | -29.08M |
| June 30, 2020 | -25.04M |
| Date | Value |
|---|---|
| March 31, 2020 | -24.66M |
| December 31, 2019 | -19.86M |
| September 30, 2019 | -19.28M |
| June 30, 2019 | -18.68M |
| March 31, 2019 | -19.45M |
| December 31, 2018 | -27.32M |
| September 30, 2018 | -16.09M |
| June 30, 2018 | -15.77M |
| March 31, 2018 | -15.34M |
| December 31, 2017 | -6.655M |
| September 30, 2017 | -6.723M |
| June 30, 2017 | -3.329M |
| March 31, 2017 | -2.678M |
| December 31, 2016 | -12.97M |
| September 30, 2016 | -11.13M |
| June 30, 2016 | -8.684M |
| March 31, 2016 | -10.07M |
| December 31, 2015 | -8.172M |
| September 30, 2015 | -55.96M |
| June 30, 2015 | -2.387M |
| March 31, 2015 | -1.462M |
| December 31, 2014 | -2.148M |
| September 30, 2014 | -2.388M |
| June 30, 2014 | -2.847M |
| March 31, 2014 | -2.148M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | -123.21M |
| EPS Diluted (Quarterly) | 1.076 |
| Enterprise Value | 29.14M |
| Earnings Yield | -7.02% |
| Normalized Earnings Yield | -7.025 |